Trial Profile
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs V 160 (Primary) ; Aluminium phosphate
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 09 Jul 2021 Status changed from active, no longer recruiting to completed.
- 08 Apr 2021 Planned End Date changed from 6 Jul 2021 to 20 Jun 2021.
- 10 Feb 2021 Planned End Date changed from 31 May 2021 to 6 Jul 2021.